NCT02072967

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 97 (actual)
• Sponsor: Astellas Pharma Europe B.V. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma

Conditions

• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
OTHER	Ribomustin	Routine practice
OTHER	rituximab	Routine practice

Timeline

• Start date: 2012-05-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-02-27
• Last updated: 2016-02-22

Locations

35 sites across 1 country: Russia